Northwest Biotherapeutics to Acquire Advent BioServices, Streamlining Operations and Enhancing Scale-Up Potential
Reuters
Aug 28
<a href="https://laohu8.com/S/NWBO">Northwest Biotherapeutics</a> to Acquire Advent BioServices, Streamlining Operations and Enhancing Scale-Up Potential
Northwest Biotherapeutics, Inc. has announced an agreement to acquire Advent BioServices Ltd. from Toucan Holdings LLC. Upon completion of the transaction, Advent will become a wholly owned subsidiary, allowing Northwest Biotherapeutics to integrate its manufacturing and product development operations internally. This acquisition is expected to enhance operational scalability and yield cost efficiencies. The agreement includes the transfer of Advent's fixed assets and intellectual property to Northwest Biotherapeutics, along with 19 million NWBio securities previously issued to Advent. Payment for the acquisition will be made in installments over two years, starting 90 days post-agreement, with potential acceleration contingent on regulatory approval of the DCVax®-L product.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF60439) on August 27, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.